The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - AXA INVESTMENT MANAGERS: Redx Pharma PLC

2 Jan 2020 12:57



Form 8.3 - AXA INVESTMENT MANAGERS: Redx Pharma PLC

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:AXA INVESTMENT MANAGERS
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. 
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeREDX PHARMA PLC
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: 
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure31st December 2019
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: 10p ordinary
InterestsShort positions
 Number%Number%
(1) Relevant securities owned and/or controlled:12,286,2209.71%  
(2) Cash-settled derivatives:     
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:    
TOTAL: AXA Investment Managers does not have discretion regarding voting decisions in respect of 392 128 shares that are included in the total above. 12,286,2209.71%  

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists: 
Details, including nature of the rights concerned and relevant percentages: 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/sale Number of securitiesPrice per unit
    

(b) Cash-settled derivative transactions

Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercise

Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable)
    

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:2nd January 2020
Contact name:Alexandra BLANCHARD
Telephone number*:+33 1 44 45 88 76

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.


Date   Source Headline
27th Oct 20227:00 amRNSRedx to Present Poster at ASN Kidney Week
11th Oct 20227:00 amRNSFirst Patient Dosed in Phase 2a Trial for RXC007
3rd Oct 20227:00 amRNSRedx Presents RXC007 Preclinical and Phase 1 Data
29th Sep 20227:41 amRNSRedx to Present Poster on RXC007 at ICLAF
6th Sep 20227:00 amRNSTR-1: Notification of major holdings
31st Aug 20227:00 amRNSRedx to Present at the ERS International Congress
5th Aug 202211:52 amRNSCompletion of Placing and Director/PDMR Dealings
3rd Aug 20221:43 pmRNSProposed Secondary Placing of Shares via ABB
26th Jul 20221:47 pmRNSExercise of Options, PDMR Dealing and TVR
11th Jul 20227:00 amRNSRedx to Present at Virtual Investor Forum
27th Jun 20227:00 amRNSEncouraging Data on Porcupine and ROCK Inhibitors
23rd Jun 20227:00 amRNSInterim Results for the Six Months Ended 31 March
20th Jun 20227:00 amRNSRedx to Present at the ECM Congress
16th Jun 20227:00 amRNSNotice of Interim Results
15th Jun 20227:00 amRNSPan-RAF Inhibitor to Enter Clinical Development
9th Jun 20224:34 pmRNSTR-1: Notification of major holdings
8th Jun 20221:28 pmRNSTR-1: Notification of major holdings
7th Jun 20228:11 amRNSAdmission of Placing Shares
6th Jun 202211:56 amRNSResults of General Meeting
30th May 20227:00 amRNSRedx Presents Poster on RXC004 at ASCO
25th May 20227:00 amRNSRedx to Present at Jefferies Healthcare Conference
20th May 20227:00 amRNSNew Grant of Options
19th May 20222:34 pmRNSNew Grant of Options
19th May 202212:14 pmRNSResult of Accelerated Bookbuild
18th May 20226:28 pmRNSLaunch of Placing via Accelerated Bookbuild
27th Apr 20223:00 pmRNSRedx to Present at ASCO
8th Apr 20226:00 pmRNSRedx Presents Encouraging RXC004 Preclinical Data
5th Apr 20227:00 amRNSCollaboration with the Garvan Institute
30th Mar 20227:00 amRNSNomination of Clinical Development Candidate
24th Mar 20227:00 amRNSRedx to Present at the AACR Annual Meeting
10th Mar 20227:00 amRNSRedx Presents Encouraging Phase 1 Data for RXC007
9th Mar 20227:00 amRNSBoard Committee Changes
8th Mar 202212:30 pmRNSResult of AGM
2nd Mar 20227:00 amRNSRedx to Present at Cowen Health Care Conference
28th Feb 20227:00 amRNSRedx to Present at ILD Summit 2022
11th Feb 20224:43 pmRNSNotice of AGM
28th Jan 20227:00 amRNSNew Grant of Share Options
27th Jan 20227:01 amRNSAppointment of Non-Executive Director
27th Jan 20227:00 amRNSFinal Audited Results and Operational Update
25th Jan 202212:00 pmRNSNotice of Preliminary Results
23rd Dec 20217:00 amRNSRedx to Receive Milestone Payment of $9m from AZ
9th Dec 20214:41 pmRNSSecond Price Monitoring Extn
9th Dec 20214:36 pmRNSPrice Monitoring Extension
9th Dec 20212:06 pmRNSSecond Price Monitoring Extn
9th Dec 20212:00 pmRNSPrice Monitoring Extension
9th Dec 20217:00 amRNSRedx to receive milestone of $10m from Jazz
6th Dec 20217:00 amRNSRedx and Caris Life Sciences Announce Partnership
30th Nov 20217:00 amRNSRedx to Participate at Piper Sandler Conference
17th Nov 20217:00 amRNSRedx to Present at Jefferies London Conference
15th Nov 20217:00 amRNSFirst Patient Dosed in Phase 2 Trial of RXC004

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.